Winstgevend schreef op 11 maart 2019 14:20:
CFO Wright noted the companys alpha-glucosidase molecule, which is designed as a replacement therapy for patients with the glycogen storage disorder Pompe disease.
The molecule under development is much closer to the naturally occurring one
than Sanofi/Genzymes already marketed Lumizyme (alglucosidase alfa), which could offer an alternative with fewer problems associated with immune reactions.
If things go well, and the new drug proves less immunogenic in clinical trials, this will provide inroads to a market worth billions, according to Wright.
Interview: Marketscreener.